Background and aims
Targeted chemotherapeutics such as cetuximab can cause many side effects such as skin toxicity when used in high concentrations. In addition, cancer cells can develop resistance to some of the anticancer agents during treatment. The lack of the desired success in chemotherapy and the development of resistance to chemotherapeutics, such as epirubicin HCl, suggest that there is a need for combined therapies. The combination of targeted chemotherapeutics and conventional chemotherapy drugs may lead to the emergence of new strategies in the treatment of cancer. In this study, cytotoxic, antiproliferative, cell cycle inhibitive, oxidative stress generation, and apoptotic effects and effect mechanisms of cetuximab alone and together with epirubicin HCl on parental liver cancer cells (P-Hep G2) and epirubicin HCl-resistant liver cancer cells (R-Hep G2) were investigated.
Materials
Cytotoxic effects of cetuximab alone and with epirubicin-HCl on cells were determined by Cell Titer-Blue® Cell Viability and Lactate Dehydrogenase Activity tests. Cell cycle distributions and apoptosis were detected by reverse transcription polymerase chain reaction (RT-PCR).
Results
Cetuximab with epirubicin HCl treatment increased the cytotoxic effect on both cells. Caspase-3/7 activity increased 3 and 1.5 times in comparison with control group in P-Hep G2 and R-Hep G2 cells, respectively, after treating with cetuximab alone, whereas the increase was found to be approximately 4.7 and 2.5 times when cetuximab was treated with epirubicin HCl in P-Hep G2 and R-Hep G2 cells, respectively. Both cetuximab alone and together with epirubicin HCl treatments caused increases in Bax/Bcl-2 ratio in both cells.
Discussion
Treatment of cetuximab with epirubicin HCl to P-Hep G2 and R-Hep G2 cells was found to be more effective in cytotoxic effect and inducing apoptosis comparison to cetuximab alone treatment. In addition, combination treatment showed different effects on pro-apoptotic/anti-apoptotic genes expression according to cells drug resistance properties.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
Ashworth, R. E., Wu, J. (2014) Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J. Hepatol. 6, 776–782.
-
Berthiaume, J. M., Wallace, K. B. (2007) Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell. Biol. Toxicol. 23, 15–25.
-
Bijwaard, K. E., Aguilera, N. S. I., Monczak, Y. T. M., Taubenberger, J. K., Jack, H., Lichy, J. H. (2001) Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin. Chem. 47, 195–201.
-
Bosetti, C., Turati, F., La Vecchia, C. (2014) Hepatocellular carcinoma epidemiology. Best. Pract. Res. Clin. Gastroenterol. 28, 753–770.
-
Bradford, M. M. (1976) A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72, 248–254.
-
Buckley, A. F., Burgart, L. J., Sahai, V., Kakar, S. (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am. J. Clin. Pathol. 129, 245–251.
-
Carvalho, A. C., Franklin, G., Dias, A. C. P., Lima, C. F. (2014) Methanolic extract of Hypericum perforatum cells elicited with Agrobacterium tumefaciens provides protection against oxidative stress induced in human HepG2 cells. Ind. Crop. Prod. 59, 177–183.
-
Chen, W., Hu, Q. D., Xia, X. F., Liang, C., Liu, H., Zhang, Q., Ma, T., Liang, F., Liang, T. B. (2014) Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells. Cancer. Biol. Ther. 15, 992–999.
-
Chen, W., Shen, X., Xia, X., Xu, G., Ma, T., Bai, X., Liang, T. (2012) NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver. Int. 32, 70–77.
-
Chuma, M., Terashita, K., Sakamoto, N. (2015) New molecularly targeted therapies against advanced hepatocellular carcinoma: from molecular pathogenesis to clinical trials and future directions. Hepatol. Res. 45, E1–E11.
-
D’angelo, D., Mussnich, P., Rosa, R., Bianco, R., Tortora, G., Fusco, A. (2014) High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer 14, 851.
-
Daveau, M., Scotte, M., François, A., Coulouarn, C., Ros, G., Tallet, Y., Hiron, M., Hellot, M. F., Salier, J. P. (2003) Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinog. 36, 130–141.
-
Ellence. (1999) Epirubicin Hydrochloride Injection, Revised Package Insert. Pharmacia & Upjohn, Perth, Australia.
-
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., Bukowski, R. M. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134.
-
Flohe, L., Gunzler, W. A. (1984) Glutathione peroxidase. Methods. Enzymol. 105, 115–121.
-
Forner, A., Llovet, J. M., Bruix, J. (2012) Hepatocellular carcinoma. Lancet 379, 1245–1255.
-
Gao, A. M., Ke, Z. P., Shi, F., Sun, G. C., Chen, H. (2013) Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem. Biol. Interact. 206, 100–108.
-
Gruenwald, V., Wilkens, L., Gebel, M., Greten, T. F., Kubicka, S., Ganser, A., Manns, M. P., Malek, N. P. (2007) A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results [Abstract]. J. Clin. Oncol. 25, 4598.
-
Han, Y., Zhang, J. P., Qian, J. Q., Hu, C. Q. (2015) Cardiotoxicity evaluation of anthracyclines in zebrafish (Danio rerio). J. Appl. Toxicol. 35, 241–252.
-
Harari, P. M. (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11, 689–708.
-
Harding, J., Burtness, B. (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41, 107–127.
-
Huang, S. T., Yang, R. C., Yang, L. J., Lee, P. N., Pang, J. H. S. (2003) Phyllanthus urinaria triggers the apoptosis and Bcl-2 down regulation in Lewis lung carcinoma cells. Life Sci. 72, 1705–1716.
-
Huether, A., Hopfner, M., Baradari, V., Schuppan, D., Scherubl, H. (2005) EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem. Pharmacol. 70, 1568–1578.
-
Jansson, O., Motlagh, P. B., Persson, M., Henrikson, R., Grankvist, K. (1999) Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem. Pharmacol. 58, 1801–1806.
-
Javitt, N. B. (1990) HepG2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 4, 161–168.
-
Kirkman, T. W. (1996) Statistics to Use [Online]. Retrieved August 17, 2008, from http://www.physics.csbsju.edu/stats/1996
-
Llovet, J. M., Bruix, J. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312–1327.
-
Lupberger, J., Zeisel, M. B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C. J., Turek, M., Gorke, S., Royer, C., Fischer, B., Zahid, M. N., Lavillette, D., Fresquet, J., Cosset, F. L., Rothenberg, S. M., Pietschmann, T., Patel, A. H., Pessaux, P., Doffoël, M., Raffelsberger, W., Poch, O., Mckeating, J. A., Brino, L., Baumert, T. F. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17, 589–595.
-
Mao, C., Liao, R. Y., Chen, Q. (2010) BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer. J. Cancer. Res. Clin. Oncol. 136, 1293–1294.
-
Nasr, M., Nafee, N., Saad, H., Kazem, A. (2014) Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur. J. Pharm. Biopharm. 88, 216–225.
-
Nishiwaki-Matsushima, R., Ohta, T., Nishiwaki, S., Suganuma, M., Kohyama, K., Ishikawa, T., Carmichael, W. W., Fujiki, H. (1992) Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR. J. Cancer. Res. Clin. Oncol. 118, 420–424.
-
Ozkan, A. (2007) Lymphokine-activated killer cell susceptibility in epirubicin resistant and parental human non-small cell lung cancer (NSCLC). Biologia 62, 232–237.
-
Parfitt, K., Sweetman, S. C., Blake, P. S., Parsons, A. V. (1999) The Complete Drug Reference (32nd ed.). Pharmaceutical Press, London, p. 543.
-
Radford, J. A., Margison, J. M., Swindell, R., Mad, M. J., Wilkinson, P. M., Thatcher, N. (1991) The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J. Cancer. Res. Clin. Oncol. 117, 151–156.
-
Ramalingam, M., Kim, S. J. (2014) Insulin on hydrogen peroxide-induced oxidative stress involves ROS/Ca2+ and Akt/Bcl-2 signaling pathways. Free. Radic. Res. 48, 347–356.
-
Rampias, T., Giagini, A., Siolos, S., Matsuzaki, H., Sasaki, C., Scorilas, A., Psyrri, A. (2014) RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin. Cancer. Res. 20, 2933–2946.
-
Rihova, B., Strohalm, J., Kobackova, K. (2002) Acquired and specific immunological mechanisms co-responsile for efficacy of polymer-bound drugs. J. Control. Release 78, 97–114.
-
Rothenberg, M. L., Blanke, C. D. (1999) Topoisomerase I inhibitors in the treatment of colorectal cancer. Colorectal cancer: past accomplishments and future directions II. Semin. Oncol. 26, 632–639.
-
Spinzi, G., Paggi, S. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 2497–2498.
-
Stotz, M., Gerger, A., Haybaeck, J., Kiesslich, T., Bullock, M. D., Pichler, M. (2015) Molecular targeted therapies in hepatocellular carcinoma: past, present and future. Anticancer Res. 35, 5737–5744.
-
Trissel, L. A., Parks, N. P. T., Santiago, N. M. (1991) Visual compatibility of fludarabine phosphate with antineoplastic drugs, antiinfectives, and other selected drugs during simulated Y-site injection. Am. J. Hosp. Pharm. 48, 2186–2189.
-
Van, I. S. C., Zegers, M. M., Kok, J. W., Hoekstra, D. (1997) Segregation of glucosylceramide and sphingomyelin occurs in the apical to basolateral transcytotic route in HepG2 cells. J. Cell. Biol. 137, 347–357.
-
Williams, D. A., Lokich, J. (1992) A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions. Cancer. Chemother. Pharmacol. 31, 171–181.
-
Yang, J. D., Roberts, L. R. (2010) Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 7, 448–458.
-
Yang, Y., Yan, J., Huang, Y., Xu, H., Zhang, Y., Hu, R., Jiang, J., Chen, Z., Jiang, H. (2015) The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. Biomed. Pharmacother. 70, 181–189.
-
Zhao, Y. N., Cao, J., Wu, F. X., Ou, C., Yuan, W. P., Mo, Q. G., Wei, W., Li, Y., Su, J. J., Liang, A. M. (2004) Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Ai. Zheng. 23, 762–766.
-
Zhu, A. X., Stuart, K., Blaszkowsky, L. S., Muzikansky, A., Reitberg, D. P., Clark, J. W., Enzinger, P. C., Bhargava, P., Meyerhardt, J. A., Horgan, K., Fuchs, C. S., Ryan, D. P. (2007) Cetuximab Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110, 581–589.
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Aug 2020 | 14 | 0 | 0 |
| Sep 2020 | 11 | 0 | 0 |
| Oct 2020 | 9 | 0 | 0 |
| Nov 2020 | 14 | 1 | 0 |
| Dec 2020 | 16 | 0 | 0 |
| Jan 2021 | 3 | 0 | 0 |
| Feb 2021 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory